129 related articles for article (PubMed ID: 15290911)
1. Circulating monocytes and plasma inflammatory biomarkers in active Crohn's disease: elevated oxidized low-density lipoprotein and the anti-inflammatory effect of atorvastatin.
Grip O; Janciauskiene S; Lindgren S
Inflamm Bowel Dis; 2004 May; 10(3):193-200. PubMed ID: 15290911
[TBL] [Abstract][Full Text] [Related]
2. Use of atorvastatin as an anti-inflammatory treatment in Crohn's disease.
Grip O; Janciauskiene S; Bredberg A
Br J Pharmacol; 2008 Dec; 155(7):1085-92. PubMed ID: 18806816
[TBL] [Abstract][Full Text] [Related]
3. Atorvastatin reduces plasma MCP-1 in patients with acute coronary syndrome.
Xu ZM; Zhao SP; Li QZ; Nie S; Zhou HN
Clin Chim Acta; 2003 Dec; 338(1-2):17-24. PubMed ID: 14637261
[TBL] [Abstract][Full Text] [Related]
4. Effects of atorvastatin, simvastatin, and fenofibrate therapy on monocyte chemoattractant protein-1 secretion in patients with hyperlipidemia.
Kowalski J; Okopień B; Madej A; Zieliński M; Belowski D; Kalina Z; Herman ZS
Eur J Clin Pharmacol; 2003 Jul; 59(3):189-93. PubMed ID: 12756509
[TBL] [Abstract][Full Text] [Related]
5. Atorvastatin decreases C-reactive protein-induced inflammatory response in pulmonary artery smooth muscle cells by inhibiting nuclear factor-kappaB pathway.
Li J; Li JJ; He JG; Nan JL; Guo YL; Xiong CM
Cardiovasc Ther; 2010; 28(1):8-14. PubMed ID: 20074254
[TBL] [Abstract][Full Text] [Related]
6. Atorvastatin therapy in hypercholesterolemic patients suppresses cellular uptake of oxidized-LDL by differentiating monocytes.
Fuhrman B; Koren L; Volkova N; Keidar S; Hayek T; Aviram M
Atherosclerosis; 2002 Sep; 164(1):179-85. PubMed ID: 12119208
[TBL] [Abstract][Full Text] [Related]
7. Atorvastatin suppresses inflammatory response induced by oxLDL through inhibition of ERK phosphorylation, IκBα degradation, and COX-2 expression in murine macrophages.
Shao Q; Shen LH; Hu LH; Pu J; Jing Q; He B
J Cell Biochem; 2012 Feb; 113(2):611-8. PubMed ID: 21956776
[TBL] [Abstract][Full Text] [Related]
8. Monocyte chemoattractant protein-1 expression is enhanced by granulocyte-macrophage colony-stimulating factor via Jak2-Stat5 signaling and inhibited by atorvastatin in human monocytic U937 cells.
Tanimoto A; Murata Y; Wang KY; Tsutsui M; Kohno K; Sasaguri Y
J Biol Chem; 2008 Feb; 283(8):4643-51. PubMed ID: 18089573
[TBL] [Abstract][Full Text] [Related]
9. Atorvastatin reduces NF-kappaB activation and chemokine expression in vascular smooth muscle cells and mononuclear cells.
Ortego M; Bustos C; Hernández-Presa MA; Tuñón J; Díaz C; Hernández G; Egido J
Atherosclerosis; 1999 Dec; 147(2):253-61. PubMed ID: 10559511
[TBL] [Abstract][Full Text] [Related]
10. Effect of atorvastatin on low-density lipoprotein subfraction profile.
Landray MJ; Hartland A; Hubscher D; Kendall MJ; Cramb R
Ann Clin Biochem; 1999 Mar; 36 ( Pt 2)():240-1. PubMed ID: 10370746
[No Abstract] [Full Text] [Related]
11. Effect of atorvastatin on plasminogen activator inhibitor type-1 synthesis in human monocytes/macrophages.
Lopez S; Peiretti F; Bonardo B; Deprez-Beauclair P; Laouenan H; Juhan-Vague I; Nalbone G
J Cardiovasc Pharmacol; 2001 Jun; 37(6):762-8. PubMed ID: 11392473
[TBL] [Abstract][Full Text] [Related]
12. Atorvastatin-induced modulation of monocyte respiratory burst in vivo in patients with IgA nephropathy: a chronic inflammatory kidney disease.
Lundberg S; Lundahl J; Gunnarsson I; Jacobson SH
Clin Nephrol; 2010 Mar; 73(3):221-8. PubMed ID: 20178722
[TBL] [Abstract][Full Text] [Related]
13. Short- and long-term elevation of autoantibody titers against oxidized LDL in patients with acute coronary syndromes. Role of the lipoprotein-associated phospholipase A2 and the effect of atorvastatin treatment.
Papathanasiou AI; Lourida ES; Tsironis LD; Goudevenos JA; Tselepis AD
Atherosclerosis; 2008 Jan; 196(1):289-297. PubMed ID: 17140582
[TBL] [Abstract][Full Text] [Related]
14. Atorvastatin downregulates monocyte CD36 expression, nuclear NFkappaB and TNFalpha levels in type 2 diabetes.
Mandosi E; Fallarino M; Gatti A; Carnovale A; Rossetti M; Lococo E; Buchetti B; Filetti S; Lenti L; Morano S
J Atheroscler Thromb; 2010 Jun; 17(6):539-45. PubMed ID: 20134099
[TBL] [Abstract][Full Text] [Related]
15. Atorvastatin and simvastatin decrease the uptake of acetylated low-density lipoprotein by human monocytes.
Tavridou A; Manolopoulos VG
Pharmacology; 2005 Feb; 73(2):102-5. PubMed ID: 15499225
[TBL] [Abstract][Full Text] [Related]
16. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors increase the binding activity and nuclear level of Oct-1 in mononuclear cells.
Ortego M; Hernández AG; Bustos C; Blanco-Colio LM; Hernández-Presa MA; Tuñón J; Egido J
Eur J Pharmacol; 2002 Jul; 448(2-3):113-21. PubMed ID: 12144930
[TBL] [Abstract][Full Text] [Related]
17. Atorvastatin activates PPAR-gamma and attenuates the inflammatory response in human monocytes.
Grip O; Janciauskiene S; Lindgren S
Inflamm Res; 2002 Feb; 51(2):58-62. PubMed ID: 11926313
[TBL] [Abstract][Full Text] [Related]
18. Intensive Statin Therapy Compromises the Adiponectin-AdipoR Pathway in the Human Monocyte-Macrophage Lineage.
Gasbarrino K; Hafiane A; Zheng H; Daskalopoulou SS
Stroke; 2019 Dec; 50(12):3609-3617. PubMed ID: 31648632
[TBL] [Abstract][Full Text] [Related]
19. Increased circulating CC chemokine levels in the metabolic syndrome are reduced by low-dose atorvastatin treatment: evidence from a randomized controlled trial.
Loughrey BV; McGinty A; Young IS; McCance DR; Powell LA
Clin Endocrinol (Oxf); 2013 Dec; 79(6):800-6. PubMed ID: 23170936
[TBL] [Abstract][Full Text] [Related]
20. Resveratrol protects against atherosclerosis, but does not add to the antiatherogenic effect of atorvastatin, in APOE*3-Leiden.CETP mice.
Berbée JF; Wong MC; Wang Y; van der Hoorn JW; Khedoe PP; van Klinken JB; Mol IM; Hiemstra PS; Tsikas D; Romijn JA; Havekes LM; Princen HM; Rensen PC
J Nutr Biochem; 2013 Aug; 24(8):1423-30. PubMed ID: 23337345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
